Moxifloxacin Krka

Moxifloxacin, the active ingredient in Moxifloxacin Krka, is a fluoroquinolone antibiotic presented as an intravenous injection solution for intravenous use. It treats a range of serious bacterial infections, including community‑acquired pneumonia, sinusitis, skin and soft‑tissue infections, intra‑abdominal infections, and complicated urinary tract infections in adult patients.

GNH USA supplies Moxifloxacin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections in several organ systems. - Community‑acquired bacterial pneumonia: rapid bacterial eradication leading to clinical improvement and reduced mortality. - Acute bacterial sinusitis: eradicates causative pathogens, relieving sinus inflammation and symptoms. - Skin and soft tissue infections: eliminates susceptible organisms, promoting wound healing and infection control. - Intra‑abdominal infections: provides broad‑spectrum coverage of Gram‑negative and anaerobic bacteria, aiding recovery. - Complicated urinary tract infections: clears resistant uropathogens, improving urinary symptoms and preventing complications.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea - Diarrhea - Headache - Injection site pain Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Clostridioides difficile‑associated colitis

When using Moxifloxacin, clinicians should observe several precautionary measures to minimize risk. - Assess renal and hepatic function: adjust therapy in patients with impairment. - Monitor cardiac status: avoid in patients with known QT prolongation or electrolyte disturbances. - Avoid use in patients with a history of tendon disorders: risk of tendon rupture. - Use cautiously in the elderly and in those receiving concomitant nephrotoxic or ototoxic drugs. - Review concomitant medications that may prolong QT interval: consider alternative agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with several medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Antacids or supplements containing aluminum, magnesium, calcium, or iron: reduce moxifloxacin absorption. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Cyclosporine: raises moxifloxacin plasma levels, heightening toxicity. Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of central nervous system stimulation. - Diuretics causing hypokalemia: can exacerbate QT interval prolongation. - Oral contraceptives: possible reduction in contraceptive effectiveness.